In particular, the CHEK2 c.1100del variant, identified in this cohort, is associated with an estimated two‐ to threefold increased risk of breast cancer in women and a 10‐fold increased risk in men (CHEK2 Consortium, 2004; Weischer et al., 2007). Here, CHEK2 is linked to breast carcinoma.